Moreover, PSA activatable peptide prodrugs of phosphoramide mustard and emetine containing a PSA peptide substrate have also been developed for prostate cancer treatment (Wu and Hu, 2016; Akinboye et al., 2017). The gene discussed is KLK3; the disease is prostate carcinoma.